Robert Rehfuss
Bristol-Myers Squibb (Germany)(DE)Bristol-Myers Squibb (United States)(US)Bristol-Myers Squibb (Sweden)(SE)
Publications by Year
Research Areas
Antiplatelet Therapy and Cardiovascular Diseases, Adenosine and Purinergic Signaling, DNA and Nucleic Acid Chemistry, Synthesis of β-Lactam Compounds, Advanced biosensing and bioanalysis techniques
Most-Cited Works
- → The cAMP-regulated enhancer-binding protein ATF-1 activates transcription in response to cAMP-dependent protein kinase A.(1991)227 cited
- → A dominant repressor of cyclic adenosine 3',5'-monophosphate (cAMP)-regulated enhancer-binding protein activity inhibits the cAMP-mediated induction of the somatostatin promoter in vivo.(1992)206 cited
- → Esperamicins, a class of potent antitumor antibiotics: mechanism of action.(1989)119 cited
- → Conformationally Constrained ortho-Anilino Diaryl Ureas: Discovery of 1-(2-(1′-Neopentylspiro[indoline-3,4′-piperidine]-1-yl)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea, a Potent, Selective, and Bioavailable P2Y1 Antagonist(2013)69 cited
- → Engineering of a Novel Anti-CD40L Domain Antibody for Treatment of Autoimmune Diseases(2014)67 cited
- → Site-specific binding constants for actinomycin D on DNA determined from footprinting studies(1992)62 cited